MCID: PHS001
MIFTS: 40

Phosphorus Metabolism Disease

Categories: Metabolic diseases

Aliases & Classifications for Phosphorus Metabolism Disease

MalaCards integrated aliases for Phosphorus Metabolism Disease:

Name: Phosphorus Metabolism Disease 12 15
Phosphorus Metabolism Disorders 45 74
Disorder of Phosphorus Metabolism 12
Phosphorus Metabolism Disorder 12
Phosphorus Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2485
ICD9CM 36 275.3
MeSH 45 D010760
NCIt 51 C97095
SNOMED-CT 69 87049008
UMLS 74 C0031707

Summaries for Phosphorus Metabolism Disease

MalaCards based summary : Phosphorus Metabolism Disease, also known as phosphorus metabolism disorders, is related to hypophosphatemia and hypophosphatemic rickets, autosomal dominant. An important gene associated with Phosphorus Metabolism Disease is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are Signaling by FGFR2 and Parathyroid hormone synthesis, secretion and action. The drugs Calcium Carbonate and Nicotinamide have been mentioned in the context of this disorder. Affiliated tissues include kidney and bone, and related phenotypes are growth/size/body region and homeostasis/metabolism

Related Diseases for Phosphorus Metabolism Disease

Diseases related to Phosphorus Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Related Disease Score Top Affiliating Genes
1 hypophosphatemia 30.6 DMP1 FAM20C FGF23 PHEX PTH SLC34A1
2 hypophosphatemic rickets, autosomal dominant 30.3 FGF23 GALNT3 PHEX SLC34A3
3 autosomal recessive hypophosphatemic rickets 30.1 DMP1 FGF23 GALNT3 PHEX
4 vitamin d-dependent rickets, type 2a 29.9 CYP27B1 PHEX VDR
5 hyperphosphatemia 29.8 CASR FGF23 GALNT3 GNAS KL PHEX
6 hypophosphatemic rickets, x-linked dominant 29.4 DMP1 FGF23 KL PHEX PTH SLC34A1
7 hypophosphatemic rickets with hypercalciuria, hereditary 28.4 CYP27B1 DMP1 FGF23 GALNT3 KL PHEX
8 tracheal calcification 10.4 FGF23 KL
9 opsismodysplasia 10.3 FGF23 PHEX
10 hereditary hypophosphatemic rickets 10.3 SLC34A1 SLC34A3
11 impaired renal function disease 10.3 FGF23 PTH
12 hypocalciuric hypercalcemia, familial, type i 10.2 CASR PTH
13 hypocalciuric hypercalcemia, familial, type ii 10.2 CASR PTH
14 hypocalciuric hypercalcemia, familial, type iii 10.2 CASR PTH
15 urinary system disease 10.2 FGF23 KL PTH
16 hypoparathyroidism, familial isolated 10.2 CASR PTH
17 tumoral calcinosis, hyperphosphatemic, familial, 1 10.2 FGF23 GALNT3 KL
18 hyperostosis 10.2 FGF23 GALNT3 KL
19 familial isolated hyperparathyroidism 10.2 CASR PTH
20 hypophosphatasia, adult 10.2
21 acid phosphatase deficiency 10.2
22 hypophosphatasia, infantile 10.2
23 hypophosphatasia, childhood 10.2
24 hypophosphatasia 10.2
25 prenatal benign hypophosphatasia 10.2
26 connective tissue benign neoplasm 10.2 GNAS PTH
27 hypothyroidism, congenital, nongoitrous, 1 10.1 GNAS STX16
28 familial hypocalciuric hypercalcemia 10.1 CASR PTH
29 arterial calcification of infancy 10.1 FGF23 PHEX
30 hypoparathyroidism 10.1 CASR FGF23 PTH
31 pseudopseudohypoparathyroidism 10.1 GNAS PTH STX16
32 pseudohypoparathyroidism 10.1 GNAS PTH STX16
33 enthesopathy 10.1 DMP1 FGF23 PHEX
34 spondylosis 10.1 KL PTH VDR
35 pseudohypoparathyroidism, type ib 10.1 GNAS PTH STX16
36 albright's hereditary osteodystrophy 10.1 GNAS STX16
37 familial tumoral calcinosis 10.1 FGF23 GALNT3 KL PHEX
38 pulmonary alveolar microlithiasis 10.1 FGF23 PTH SLC34A1 SLC34A3
39 calcinosis 10.1 FGF23 GALNT3 KL PHEX
40 osteitis fibrosa 10.0 CASR GNAS PTH
41 metaphyseal chondrodysplasia, jansen type 10.0 FGF23 PTH
42 multiple endocrine neoplasia, type i 10.0 CASR GNAS PTH
43 hypercalcemia, infantile, 1 10.0 CASR PTH VDR
44 hypercalciuria, absorptive, 2 10.0 CASR SLC34A3 VDR
45 oncogenic osteomalacia 10.0 DMP1 FGF23 PHEX PTH
46 parathyroid adenoma 9.9 CASR PTH VDR
47 caffey disease 9.9 FAM20C GALNT3
48 idiopathic hypercalciuria 9.9 CASR SLC34A3 VDR
49 bone remodeling disease 9.9 FGF23 PHEX PTH VDR
50 uremia 9.9 CASR PTH VDR

Comorbidity relations with Phosphorus Metabolism Disease via Phenotypic Disease Network (PDN): (show all 14)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Bronchitis
Chronic Kidney Failure Decubitus Ulcer
Deficiency Anemia Heart Disease
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder

Graphical network of the top 20 diseases related to Phosphorus Metabolism Disease:



Diseases related to Phosphorus Metabolism Disease

Symptoms & Phenotypes for Phosphorus Metabolism Disease

MGI Mouse Phenotypes related to Phosphorus Metabolism Disease:

47 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.34 CASR CYP27B1 DMP1 FAM20C FGF23 GALNT3
2 homeostasis/metabolism MP:0005376 10.28 CASR CYP27B1 DMP1 FAM20C FGF23 GALNT3
3 cellular MP:0005384 10.25 CASR CYP27B1 DMP1 FAM20C GALNT3 GNAS
4 behavior/neurological MP:0005386 10.22 CASR CYP27B1 FAM20C GNAS KL PHEX
5 endocrine/exocrine gland MP:0005379 10.21 CASR CYP27B1 FAM20C FGF23 GALNT3 GNAS
6 hematopoietic system MP:0005397 10.2 CASR CYP27B1 DMP1 FAM20C FGF23 GALNT3
7 craniofacial MP:0005382 10.19 CYP27B1 DMP1 FAM20C GALNT3 GNAS KL
8 cardiovascular system MP:0005385 10.16 DMP1 FGF23 GALNT3 GNAS KL PHEX
9 immune system MP:0005387 10.14 CASR CYP27B1 DMP1 FAM20C FGF23 GALNT3
10 digestive/alimentary MP:0005381 10.13 CASR FAM20C FGF23 GALNT3 KL PHEX
11 limbs/digits/tail MP:0005371 10.02 CYP27B1 DMP1 FAM20C FGF23 GALNT3 GNAS
12 adipose tissue MP:0005375 9.97 CYP27B1 GNAS KL PHEX STX16
13 renal/urinary system MP:0005367 9.93 CASR CYP27B1 DMP1 FAM20C FGF23 GALNT3
14 integument MP:0010771 9.91 CASR CYP27B1 FGF23 GALNT3 GNAS KL
15 hearing/vestibular/ear MP:0005377 9.88 FAM20C GNAS KL PHEX VDR
16 muscle MP:0005369 9.73 CASR GALNT3 GNAS KL SLC34A1 VDR
17 reproductive system MP:0005389 9.5 CYP27B1 FAM20C FGF23 GALNT3 KL SLC34A1
18 skeleton MP:0005390 9.47 CASR CYP27B1 DMP1 FAM20C FGF23 GALNT3

Drugs & Therapeutics for Phosphorus Metabolism Disease

Drugs for Phosphorus Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 471-34-1
2
Nicotinamide Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 98-92-0 936
3
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68-04-2
4
Sevelamer Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52757-95-6
5
Calcium acetate Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 62-54-4
6
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6, 15438-31-0 27284 23925
7
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-70-2 271
8
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 1,Phase 2,Not Applicable 59-67-6 938
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 59-30-3 6037
10
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 77-92-9 311
11
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 1406-16-2
12
Calcitriol Approved, Nutraceutical Phase 4,Not Applicable,Early Phase 1 32222-06-3 5280453 134070
13
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 50-14-6 5280793
14 Lipid Regulating Agents Phase 4,Phase 1,Phase 2
15 Nicotinic Acids Phase 4,Phase 1,Phase 2,Not Applicable
16 Antimetabolites Phase 4,Phase 1,Phase 2
17 Antacids Phase 4,Phase 3,Phase 2,Not Applicable
18 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Not Applicable
21 Vitamin B Complex Phase 4,Phase 1,Phase 2,Not Applicable
22 Folate Phase 4,Phase 1,Phase 2,Not Applicable
23 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Trace Elements Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
25 Vitamin B3 Phase 4,Phase 1,Phase 2,Not Applicable
26 Micronutrients Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
27 Vasodilator Agents Phase 4,Phase 1,Phase 2,Not Applicable
28 Vitamins Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
29 Nutrients Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
30 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Hypolipidemic Agents Phase 4,Phase 1,Phase 2
32 Vitamin B9 Phase 4,Phase 1,Phase 2,Not Applicable
33 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1
34 Ferric Compounds Phase 4,Phase 3,Phase 2
35 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Citrate Phase 4,Phase 3,Phase 2,Phase 1
37 Hematinics Phase 4,Phase 3,Phase 2,Not Applicable
38 Calciferol Phase 4,Phase 3,Not Applicable,Early Phase 1
39 Vasoconstrictor Agents Phase 4,Not Applicable,Early Phase 1
40 Ergocalciferols Phase 4,Phase 3,Not Applicable
41 Vitamin D2 Phase 4,Phase 3,Not Applicable
42
Parathyroid hormone Approved, Investigational Phase 3,Phase 1 9002-64-6
43
Cinacalcet Approved Phase 3,Phase 1,Not Applicable 226256-56-0 156419
44
carbamide peroxide Approved Phase 3 124-43-6
45 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
46 Mitogens Phase 3,Phase 2,Phase 1,Not Applicable
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2,Not Applicable
48 Hormone Antagonists Phase 3,Phase 1,Phase 2,Not Applicable
49 Calcimimetic Agents Phase 3,Phase 1,Not Applicable
50 Bile Acids and Salts Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 169)
# Name Status NCT ID Phase Drugs
1 Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia Unknown status NCT02836184 Phase 4 Nicotinic Acids;Calcium Carbonate
2 A Study of Ferric Citrate to Improve Inflammation and Lipid Levels Unknown status NCT02661295 Phase 4 Ferric Citrate
3 Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients Completed NCT01755078 Phase 4 Sevelamer HCl;Calcium-based phosphate binder
4 Phosphate Kinetic Modeling 2 Completed NCT01252771 Phase 4
5 Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia Recruiting NCT03820518 Phase 4 Calcitriol
6 A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease Recruiting NCT03466983 Phase 4 Iron Isomaltoside;Ferric Carboxymaltose
7 Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Active, not recruiting NCT03256838 Phase 4 Ferric Citrate
8 Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients Active, not recruiting NCT03079869 Phase 4 Ferric Citrate
9 Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia Enrolling by invitation NCT02237534 Phase 4 Lanthanum carbonate;Calcium Carbonate
10 The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis Not yet recruiting NCT03163576 Phase 4 Niacin;Phosphate Binder
11 Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol Terminated NCT01725113 Phase 4 Calcitriol;Paricalcitol
12 A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia Completed NCT01852682 Phase 3 PA21
13 A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850641 Phase 3 PA21
14 A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850602 Phase 3 PA21;Sevelamer hydrochloride
15 A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01833494 Phase 3 PA21
16 Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study Completed NCT01578200 Phase 3 Lanthanum Carbonate;Calcium Carbonate
17 Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients Completed NCT01518387 Phase 3 Lanthanum Carbonate (BAY77-1931)
18 Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate Completed NCT01514851 Phase 3 Lanthanum carbonate (BAY77-1931);Calcium carbonate
19 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease Completed NCT01503736 Phase 3 ferric citrate;ferric citrate;ferric citrate
20 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742611 Phase 3 ASP1585
21 A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742585 Phase 3 ASP1585;placebo
22 A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis Completed NCT01057407 Phase 3 ASP1585;Sevelamer hydrochloride
23 A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis Completed NCT01017276 Phase 3 ASP1585
24 Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis Completed NCT00892749 Phase 3 ASP1585
25 EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease) Completed NCT00211978 Phase 3 calcium acetate;placebo
26 Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules Completed NCT02027662 Phase 2, Phase 3 Osvaren Granules;Osvaren film-coated tablets
27 A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis Completed NCT01554982 Phase 3 ferric citrate
28 Long-term Study in Chronic Kidney Disease (Extension From Study 14817) Completed NCT01187628 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931)
29 Study in Chronic Kidney Disease (CKD) Not on Dialysis Completed NCT01110629 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931);Placebo
30 Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients Completed NCT01069692 Phase 3 SBR759A;SBR759A;SBR759A;SBR759A;SBR759A
31 Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00772382 Phase 3 MCI-196
32 An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis Completed NCT00681941 Phase 3 Sevelamer carbonate (Renvela®)
33 A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00542815 Phase 3 MCI-196;Another Phosphate binder (Sevelamer)
34 A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia Completed NCT00506441 Phase 3 MCI-196;Placebo
35 A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia Completed NCT00416520 Phase 3 MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®);Placebo;Another phosphate binder (Sevelamer)
36 An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) Completed NCT02675998 Phase 3 Tenapanor;Placebo
37 A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis Completed NCT01191255 Phase 3 ferric citrate, ca acetate, sevelamer carbonate, placebo
38 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease Completed NCT01074125 Phase 3 ferric citrate
39 A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia Completed NCT00542386 Phase 3 MCI-196;Placebo
40 Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) Completed NCT02537431 Phase 3
41 Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) Completed NCT02526160 Phase 3
42 A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-04) Completed NCT03238911 Phase 3 Iron isomaltoside (Monofer);Ferric carboxymaltose
43 A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-05) Completed NCT03237065 Phase 3 Iron Isomaltoside (Monofer);Ferric carboxymaltose
44 Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets Completed NCT00417612 Phase 3 Paricalcitol
45 Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D Completed NCT02492620 Phase 3 Ferric Citrate
46 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients Completed NCT00975000 Phase 3 Cinacalcet;Placebo
47 Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets Completed NCT01237288 Phase 3 Z-521
48 Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Recruiting NCT03824587 Phase 2, Phase 3 Tenapanor;Placebo
49 PA21 Safety and Efficacy in Adult Chinese Subjects Recruiting NCT03644264 Phase 3 PA21;sevelamer carbonate
50 Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China Recruiting NCT03001011 Phase 3 Placebo;Sevelamer Carbonate (GZ419831)

Search NIH Clinical Center for Phosphorus Metabolism Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: phosphorus metabolism disorders

Genetic Tests for Phosphorus Metabolism Disease

Anatomical Context for Phosphorus Metabolism Disease

MalaCards organs/tissues related to Phosphorus Metabolism Disease:

42
Kidney, Bone

Publications for Phosphorus Metabolism Disease

Variations for Phosphorus Metabolism Disease

Expression for Phosphorus Metabolism Disease

Search GEO for disease gene expression data for Phosphorus Metabolism Disease.

Pathways for Phosphorus Metabolism Disease

GO Terms for Phosphorus Metabolism Disease

Cellular components related to Phosphorus Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.35 GALNT3 GNAS PHEX SLC34A1 STX16
2 apical plasma membrane GO:0016324 9.02 CASR GNAS KL SLC34A1 SLC34A3

Biological processes related to Phosphorus Metabolism Disease according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.87 DMP1 FAM20C FGF23 SLC34A1
2 cellular calcium ion homeostasis GO:0006874 9.79 CASR PTH VDR
3 ossification GO:0001503 9.78 CASR DMP1 SLC34A1
4 fibroblast growth factor receptor signaling pathway GO:0008543 9.77 FGF23 GALNT3 KL
5 skeletal system development GO:0001501 9.72 FAM20C GNAS PHEX PTH VDR
6 biomineral tissue development GO:0031214 9.67 DMP1 FAM20C PHEX
7 calcium ion homeostasis GO:0055074 9.66 CYP27B1 KL
8 response to cadmium ion GO:0046686 9.65 PTH SLC34A1
9 decidualization GO:0046697 9.65 CYP27B1 VDR
10 regulation of bone mineralization GO:0030500 9.65 CYP27B1 FGF23
11 positive regulation of bone mineralization GO:0030501 9.65 FAM20C KL PTH
12 calcium ion transport GO:0006816 9.64 CYP27B1 VDR
13 response to lead ion GO:0010288 9.64 PTH SLC34A1
14 energy reserve metabolic process GO:0006112 9.63 GNAS KL
15 positive regulation of keratinocyte differentiation GO:0045618 9.63 CYP27B1 VDR
16 response to vitamin D GO:0033280 9.63 CYP27B1 PHEX PTH
17 response to growth hormone GO:0060416 9.62 PHEX SLC34A1
18 response to magnesium ion GO:0032026 9.62 FGF23 SLC34A1
19 vitamin D metabolic process GO:0042359 9.61 CYP27B1 FGF23 VDR
20 phosphate ion transport GO:0006817 9.6 SLC34A1 SLC34A3
21 response to fibroblast growth factor GO:0071774 9.58 CASR PTH
22 sodium-dependent phosphate transport GO:0044341 9.58 SLC34A1 SLC34A3
23 cellular response to vitamin D GO:0071305 9.58 CASR FGF23 PHEX
24 dentinogenesis GO:0097187 9.56 FAM20C SLC34A1
25 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.55 FGF23 KL
26 bone mineralization GO:0030282 9.54 CYP27B1 PHEX
27 cellular response to parathyroid hormone stimulus GO:0071374 9.54 FGF23 PHEX SLC34A1
28 response to sodium phosphate GO:1904383 9.52 FGF23 PHEX
29 vitamin D catabolic process GO:0042369 9.51 CYP27B1 FGF23
30 cellular phosphate ion homeostasis GO:0030643 9.43 FGF23 SLC34A1 SLC34A3
31 phosphate ion homeostasis GO:0055062 9.33 FGF23 PTH SLC34A1
32 response to parathyroid hormone GO:0071107 9.13 GNAS PTH SLC34A1
33 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 8.8 CYP27B1 FGF23 VDR

Molecular functions related to Phosphorus Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibroblast growth factor receptor binding GO:0005104 9.26 FGF23 KL
2 sodium:phosphate symporter activity GO:0005436 9.16 SLC34A1 SLC34A3
3 sodium-dependent phosphate transmembrane transporter activity GO:0015321 8.96 SLC34A1 SLC34A3
4 vitamin D binding GO:0005499 8.62 KL VDR

Sources for Phosphorus Metabolism Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....